(0.30%) 5 115.15 points
(0.24%) 38 330 points
(0.33%) 15 980 points
(-1.09%) $82.94
(4.94%) $2.02
(0.25%) $2 353.00
(0.45%) $27.66
(3.77%) $956.90
(-0.22%) $0.933
(-0.34%) $10.99
(-0.55%) $0.796
(1.65%) $93.39
Live Chart Being Loaded With Signals
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments...
Stats | |
---|---|
Šios dienos apimtis | 4.96M |
Vidutinė apimtis | 3.25M |
Rinkos kapitalizacija | 60.48B |
EPS | HKD0.186 ( 2023-09-30 ) |
Last Dividend | HKD0.460 ( 2023-07-31 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.90 |
ATR14 | HKD0.0150 (0.12%) |
Tūris Koreliacija
Shanghai Fosun Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Shanghai Fosun Koreliacija - Valiuta/Žaliavos
Shanghai Fosun Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD41.40B |
Bruto pelnas: | HKD19.80B (47.84 %) |
EPS: | HKD0.890 |
FY | 2023 |
Pajamos: | HKD41.40B |
Bruto pelnas: | HKD19.80B (47.84 %) |
EPS: | HKD0.890 |
FY | 2022 |
Pajamos: | HKD43.95B |
Bruto pelnas: | HKD20.78B (47.28 %) |
EPS: | HKD1.430 |
FY | 2021 |
Pajamos: | HKD39.01B |
Bruto pelnas: | HKD18.78B (48.14 %) |
EPS: | HKD1.850 |
Financial Reports:
No articles found.
Shanghai Fosun Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.460 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.210 | 2013-07-04 |
Last Dividend | HKD0.460 | 2023-07-31 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | HKD4.51 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.42 | -- |
Div. Sustainability Score | 7.35 | |
Div.Growth Potential Score | 4.70 | |
Div. Directional Score | 6.03 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9989.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
2196.HK | Ex Dividend Junior | 2023-07-31 | Annually | 0 | 0.00% | |
1203.HK | Ex Dividend Junior | 2023-10-03 | Semi-Annually | 0 | 0.00% | |
0280.HK | Ex Dividend Knight | 2023-09-12 | Sporadic | 0 | 0.00% | |
3939.HK | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
1776.HK | Ex Dividend Junior | 2023-07-11 | Annually | 0 | 0.00% | |
0817.HK | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
2359.HK | Ex Dividend Knight | 2023-06-05 | Annually | 0 | 0.00% | |
1345.HK | Ex Dividend Junior | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0390.HK | Ex Dividend Junior | 2023-07-19 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0576 | 1.500 | 8.85 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0210 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0523 | 1.500 | -0.530 | -0.795 | [0.1 - 1] |
payoutRatioTTM | 1.029 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.001 | 0.800 | 9.99 | 8.00 | [1 - 3] |
quickRatioTTM | 0.757 | 0.800 | -0.254 | -0.203 | [0.8 - 2.5] |
cashRatioTTM | 0.406 | 1.500 | 8.86 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.84 | -7.26 | [0 - 0.6] |
interestCoverageTTM | 2.50 | 1.000 | -0.186 | -0.186 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.173 | 2.00 | 9.61 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.601 | 2.00 | -0.301 | -0.601 | [0 - 20] |
debtEquityRatioTTM | 0.769 | -1.500 | 6.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.478 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0799 | 1.000 | -0.402 | -0.402 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.100 | 1.000 | -0.553 | -0.553 | [0.2 - 2] |
assetTurnoverTTM | 0.365 | 0.800 | -0.901 | -0.721 | [0.5 - 2] |
Total Score | 7.35 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.55 | 1.000 | 8.63 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0523 | 2.50 | -0.341 | -0.795 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.601 | 2.00 | -0.200 | -0.601 | [0 - 30] |
dividendYielPercentageTTM | 3.98 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.173 | 2.00 | 9.61 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.029 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 6.62 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0852 | 1.000 | -0.370 | 0 | [0.1 - 0.5] |
Total Score | 4.70 |
Shanghai Fosun
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.